Abeona Therapeutics Inc. ABEO
5.40
(0.03)
(0.55%)
as of 25 Sep
- Market cap
- $303.8M
- P/E
- 0.0×
Follow ABEO
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (43.13%) | 70.99% | 70.05% | 75.90% |
+8 more TTM periods Free account |
|
| (29.54%) | 44.41% | 43.34% | 46.83% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(41.95%) | 40.70% | 40.37% | 40.31% | |
Average Days of Receivables |
139.25 | 135.74 | 261.08 | 0.00 | |
Free Cash Flow per Share |
(1.43) | (1.51) | (1.59) | (1.52) | |
Free Cash Flow |
(81.53) | (85.24) | (84.30) | (82.36) | |
Capital Expenditures |
(5.09) | (7.51) | (7.97) | (7.43) | |
Piotroski F-Score |
2.00 | 5.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(26.37%) | (23.46%) | (20.59%) | (18.81%) | |
Accounts Receivable Turnover |
4.50 | 4.33 | 2.24 | 0.00 | |
Accounts Payable Turnover |
1.63 | 0.94 | 0.41 | 0.65 | |
Inventory Turnover |
1.95 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
130.02 | 348.97 | 1,244.91 | 760.67 | |
Days of Inventory on Hand |
257.13 | 518.95 | 866.82 | 622.45 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
98.40% | 146.49% | 285.60% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
283.31% | 414.34% | 692.70% | 0.00% | |
Share Based Compensation of Revenue |
44.65% | 71.47% | 114.82% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.22 | (1.18) | (1.07) | (0.91) | |
Depreciation/Fixed assets |
0.36 | 0.34 | 3.59 | 0.31 | |
Capex/Depreciation |
(1.38) | (2.08) | (2.24) | (2.29) | |
Revenue per Share |
0.45 | 0.32 | 0.18 | 0.00 | |
Operating CF per Share |
(1.34) | (1.37) | (1.44) | (1.38) | |
Capex per Share |
(0.09) | (0.13) | (0.15) | (0.14) | |
Capex to Sales |
0.20 | 0.42 | 0.85 | 0.00 | |
Net Profit Margin |
(242.62%) | 366.61% | 758.23% | 0.00% |
Columns are period end dates